Depomed (DEPO) Tops Q3 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. NVDA
7. CRBU
8. BBIO
9. RCKT
10. OPCH

Go back to Depomed (DEPO) Tops Q3 EPS by 14c

Depomed Reports Record Sales in Third Quarter 2015 and Raises Full Year 2015 Guidance

November 9, 2015 4:01 PM EST

NEWARK, Calif., Nov. 9, 2015 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended September 30, 2015.

"Depomed is now one of the top U.S. companies in pain and neurology.  In the third quarter, the company achieved historic highs in product sales, driven by significant growth in both prescriptions and market share," said Jim Schoeneck, President and CEO of Depomed. "Our new flagship franchise NUCYNTA, which we began promoting in June, led the way with revenue growing 15% over the prior... More